Have a personal or library account? Click to login
Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link Cover

Exposure to Asbestos and Increased Intrahepatic Cholangiocarcinoma Risk: Growing Evidences of a Putative Causal Link

Annals of Global Health
Volume 88 (2022): Issue 1
By: Giovanni Brandi,  Kurt Straif,  Daniele Mandrioli,  Stefania Curti,  Stefano Mattioli and  Simona Tavolari  
Open Access
|Jun 2022

References

  1. 1Khan SA, Tavolari S, Brandi G. Cholangiocarcinoma: Epidemiology and risk factors. Liver Int. 2019; 39: 19–31. DOI: 10.1111/liv.14095
    Back to article
  2. 2Saha SK, Zhu AX, Fuchs CS, Brooks GA. Forty-year trends in cholangiocarcinoma incidence in the U.S.: Intrahepatic disease on the rise. Oncologist. 2016; 21: 594–599. DOI: 10.1634/theoncologist.2015-0446
    Back to article
  3. 3Ransome E, Tong L, Espinosa J, Chou J, Somnay V, Munene G. Trends in surgery and disparities in receipt of surgery for intrahepatic cholangiocarcinoma in the US: 2005–2014. J Gastrointest Oncol. 2019; 10: 339–347. DOI: 10.21037/jgo.2018.12.07
    Back to article
  4. 4Hainsworth JD, Rubin MS, Spigel DR, et al. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: A prospective trial of the Sarah Cannon research institute. J Clin Oncol. 2013; 31: 217–223. DOI: 10.1200/JCO.2012.43.3755
    Back to article
  5. 5IARC Monographs, Vol. 100B.
    Back to article
  6. 6Kumagai S, Sobue T, Makiuchi T, et al. Relationship between cumulative exposure to 1,2-dichloropropane and incidence risk of cholangiocarcinoma among offset printing workers. Occup Environ Med. 2016; 73: 545–552. DOI: 10.1136/oemed-2015-103427
    Back to article
  7. 7IARC Monographs, Vol. 110.
    Back to article
  8. 8Mimaki S, Totsuka Y, Suzuki Y, et al. Hypermutation and unique mutational signatures of occupational cholangiocarcinoma in printing workers exposed to haloalkanes. Carcinogenesis. 2016; 37: 817–826. DOI: 10.1093/carcin/bgw066
    Back to article
  9. 9Selikoff IJ, Seidman H. Asbestos-associated deaths among insulation workers in the United States and Canada, 1967–1987. Ann. N. Y. Acad. Sci. 1991; 643: 1–14. DOI: 10.1111/j.1749-6632.1991.tb24439.x
    Back to article
  10. 10Wu WT, Lin YJ, Li CY, et al. Cancer attributable to asbestos exposure in shipbreaking workers: A matched-cohort study. PLoS One. 2015; 10: e0133128. DOI: 10.1371/journal.pone.0133128
    Back to article
  11. 11Luberto F, Ferrante D, Silvestri S, et al. Cumulative asbestos exposure and mortality from asbestos related diseases in a pooled analysis of 21 asbestos cement cohorts in Italy. Environ Health. 2019; 18: 71. DOI: 10.1186/s12940-019-0510-6
    Back to article
  12. 12Brandi G, Di Girolamo S, Farioli A, et al. Asbestos: A hidden player behind the cholangiocarcinoma increase? Findings from a case-control analysis. Cancer Causes Control. 2013; 24: 911–918. DOI: 10.1007/s10552-013-0167-3
    Back to article
  13. 13Farioli A, Straif K, Brandi G, et al. Occupational exposure to asbestos and risk of cholangiocarcinoma: A population-based case-control study in four Nordic countries. Occup Environ Med. 2018; 75: 191–198. DOI: 10.1136/oemed-2017-104603
    Back to article
  14. 14Grosso F, Randi L, Croce A, et al. Asbestos fibers in the gallbladder of patients affected by benign biliary tract diseases. Eur J Gastroenterol Hepatol. 2015; 27: 860–864. DOI: 10.1097/MEG.0000000000000357
    Back to article
  15. 15Grosso F, Croce A, Libener R, et al. Asbestos fiber identification in liver from cholangiocarcinoma patients living in an asbestos polluted area: A preliminary study. Tumori. 2019; 105: 404–410. DOI: 10.1177/0300891619839305
    Back to article
  16. 16Auerbach O, Conston AS, Garfinkel L, Parks VR, Kaslow HD, Hammond EC. Presence of asbestos bodies in organs other than the lung. Chest. 1980; 77: 133–7. DOI: 10.1378/chest.77.2.133
    Back to article
  17. 17Langer AM. Inorganic particles in human tissues and their association with neoplastic disease. Environ Health Perspect. 1974; 9: 229–33. DOI: 10.1289/ehp.749229
    Back to article
  18. 18Padmore T, Stark C, Turkevich LA, Champion JA. Quantitative analysis of the role of fiber length on phagocytosis and inflammatory response by alveolar macrophages. Biochim. Biophys. Acta Gen. Subj. 2017; 1861: 58–67. DOI: 10.1016/j.bbagen.2016.09.031
    Back to article
  19. 19Mäki-Nevala S, Sarhadi VK, Knuuttila A, et al. Driver Gene and Novel Mutations in Asbestos-Exposed Lung Adenocarcinoma and Malignant Mesothelioma Detected by Exome Sequencing. Lung. 2016; 194: 125–135. DOI: 10.1007/s00408-015-9814-7
    Back to article
  20. 20Nymark P, Aavikko M, Mäkilä J, et al. Accumulation of genomic alterations in 2p16, 9q33.1 and 19p13 in lung tumours of asbestos-exposed patients. Mol Oncol. 2013; 7: 29–40. DOI: 10.1016/j.molonc.2012.07.006
    Back to article
  21. 21Bueno R, Stawiski EW, Goldstein LD, et al. Comprehensive genomic analysis of malignant pleural mesothelioma identifies recurrent mutations, gene fusions and splicing alterations. Nat Genet. 2016; 48: 407–416. DOI: 10.1038/ng.3520
    Back to article
  22. 22Hmeljak J, Sanchez-Vega F, Hoadley KA, et al. Integrative molecular characterization of malignant pleural mesothelioma. Cancer Discov. 2018; 8(12): 1548–1565. DOI: 10.1158/2159-8290.CD-18-0804
    Back to article
  23. 23Brandi G, Deserti M, Astolfi A, et al. Whole-exome sequencing analysis identifies recurrent mutation rate in BAP1 gene in intrahepatic cholangiocarcinoma patients exposed to asbestos. Annals of Oncology. 2017; 28: vi47. DOI: 10.1093/annonc/mdx425.011
    Back to article
  24. 24Brandi G, Deserti M, Palloni A, et al. Intrahepatic cholangiocarcinoma development in a patient with a novel BAP1 germline mutation and low exposure to asbestos. Cancer Genet. 2020; 248–249: 57–62. DOI: 10.1016/j.cancergen.2020.10.001
    Back to article
  25. 25Mosbeh A, Halfawy K, Abdel-Mageed WS, Sweed D, Rahman MHA. Nuclear BAP1 loss is common in intrahepatic cholangiocarcinoma and a subtype of hepatocellular carcinoma but rare in pancreatic ductal adenocarcinoma. Cancer Genet. 2018 Aug; 224–225: 21–28. DOI: 10.1016/j.cancergen.2018.03.002
    Back to article
  26. 26Kittaneh M, Berkelhammer C. Detecting germline BAP1 mutations in patients with peritoneal mesothelioma: Benefits to patient and family members. J Transl Med. 2018; 16(1): 194. Published July 13, 2018. DOI: 10.1186/s12967-018-1559-7
    Back to article
  27. 27Carbone M, Yang H, Pass HI, Krausz T, Testa JR, Gaudino G. BAP1 and cancer. Nat Rev Cancer. 2013; 13: 153–159. DOI: 10.1038/nrc3459
    Back to article
  28. 28Masoomian B, Shields JA, Shields CL. Overview of BAP1 cancer predisposition syndrome and the relationship to uveal melanoma. J Curr Ophthalmol. 2018; 30: 102–109. DOI: 10.1016/j.joco.2018.02.005
    Back to article
  29. 29Furuya S, Chimed-Ochir O, Takahashi K, David A, Takala J. Global Asbestos Disaster. Int J Environ Res Public Health. May 16, 2018; 15(5): 1000. DOI: 10.3390/ijerph15051000
    Back to article
  30. 30Banales JM, Marin JJG, Lamarca A, et al. Cholangiocarcinoma 2020: The next horizon in mechanisms and management. Nat Rev Gastroenterol Hepatol. 2020; 17: 557–588. DOI: 10.1038/s41575-020-0310-z
    Back to article
  31. 31Exposure to hazardous chemicals at work and resulting health impacts: A global review International Labour Office. Geneva: ILO, 2021.
    Back to article
DOI: https://doi.org/10.5334/aogh.3660 | Journal eISSN: 2214-9996
Journal RSS Feed
Language: English
Submitted on: Dec 9, 2021
Accepted on: May 25, 2022
Published on: Jun 13, 2022
Published by: Ubiquity Press
In partnership with: Paradigm Publishing Services
Publication frequency: 1 issue per year
Keywords:
intrahepatic cholangiocarcimona,
asbestos,
risk factors

© 2022 Giovanni Brandi, Kurt Straif, Daniele Mandrioli, Stefania Curti, Stefano Mattioli, Simona Tavolari, published by Ubiquity Press
This work is licensed under the Creative Commons Attribution 4.0 License.

Previous articleVolume 88 (2022): Issue 1Next article